• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Neurologic Cancers: Selections from “The World Market for Neurotherapeutic Drugs”

$1,121.00 – $1,717.00

Clear
SKU: KLI847932 Category: Pharmaceuticals Market Research Pages: 250
  • Description
  • Table of Contents
  • Latest reports

Description

In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.

Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.

Among the selections, you’ll find:

I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how oncology therapeutics fit in.

II. Introduction (31 pages) —Selection includes the overview of neurologic cancer, including prevalence estimates.

III. Treatment (11 pages) —This selection reviews current treatment protocols and the agents used in various forms of brain and spinal tumors.

IV. Progress and Promise in Therapeutic Development (62 pages) —Because progress on other neurotherapeutic fronts can have significant impact on oncology, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to cancer includes Table 4-4: Active Clinical Trials Involving Neurologic Cancers.

V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete projections and growth rates for neurologic cancer treatment potential in each of the top world markets. Growth rates for other major neurological diseases are included, along with total world numbers for comparison.

VI. Company Profiles (50 pages) —Profiles of the following companies are included:

  • Boston Life Sciences, Inc.
  • Cephalon, Inc.
  • Curis, Inc.
  • D-Pharm Ltd.
  • Guilford Pharmaceuticals Inc.
  • NeoTherapeutics, Inc.
  • Neurobiological Technologies, Inc.
  • Neurocrine BioSciences, Inc.
  • Titan Pharmaceuticals, Inc.

VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.

VIII. Glossary (8 pages)

IX. Company Directory (8 pages)

Table of Contents

Executive Summary

  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends

Overview of Neurologic Diseases and Disorders

Background

      • History
      • Neurologic Examination
      • Diagnostic Procedures

Pathophysiology

      • Peripheral Nerve and Skeletal Muscle Diseases and Disorders
      • Central Nervous System Diseases and Disorders

Key Neurologic Diseases and Disorders

    • Brain and Spinal Tumors
    • Neurofibromatosis

Treatment of Neurologic Diseases and Disorders

Cancer

Progress and Promise in Therapeutics Development

Genetics and Neurogenomics

Neural Implant Technologies

Miscellaneous Advances

      • Vascular Endothelial Growth Factor (VEGF)
      • Minocycline
      • Stroke and Apoptosis

Clinical Trial Activity

World Market Analysis

Background

The Markets by Geography

      • The United States
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
      • Japan

The Market by Applications

    • Brain/Neurologic Cancers

Company Profiles

  • Boston Life Sciences, Inc.
  • Cephalon, Inc.
  • Curis, Inc.
  • D-Pharm Ltd.
  • Guilford Pharmaceuticals Inc.
  • NeoTherapeutics, Inc.
  • Neurobiological Technologies, Inc.
  • Neurocrine BioSciences, Inc.
  • Titan Pharmaceuticals, Inc.

Conclusions and Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion

Glossary

Company Directory

List of Exhibits

  • Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 2-1: Neurologic Diseases and Disorders as Classified by the United States National Institute of Neurological Disorders and Stroke 2002
  • Table 2-2: Classification of Diseases and Disorders of Peripheral Nerve and Skeletal Muscle
  • Table 2-3: Classification of Diseases and Disorders of the Central Nervous System
  • Table 3-7: Therapies for Key Neurologic Cancers
  • Table 4-4: Active Clinical Trials Involving Neurologic Cancers
  • Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
  • Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
  • Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
  • Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
  • Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
  • Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
  • Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
  • Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010
  • Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
  • Table 5-12: The Potential for Brain and Neurologic Cancer Therapeutics in the Major World Healthcare Markets 2001-2010
  • Table 5-19: The Potential for Spinal Cord Injury Therapeutics in the Major World Healthcare Markets 2001-2010
  • Table 5-20: The Potential for Stroke Therapeutics in the Major World Healthcare Markets 2001-2010
  • Table 5-21: The Potential for Traumatic Brain Injury Therapeutics in the Major World Healthcare Markets 2001-2010
  • Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
  • Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
  • Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Application, 2001-2009
  • Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
  • Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
  • Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
  • Figure 2-1: Structure of the Normal Motor Neuron
  • Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
  • Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
  • Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12:
  • Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
  • Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
  • Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
  • Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major World Healthcare Markets, 2001-2010
  • Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
  • Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
  • Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002
    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Rheumatoid Arthritis: The 45 Market in the United States for Drugs and Biologics

    $2,246.00 – $4,492.00
  • Placeholder image

    World Market for Anti-infectives Series: Volumes I – III – Antifungals, Antibacterials and Antivirals, The

    $6,000.00 – $12,000.00
  • Placeholder image

    Growth Factors: Indications, Products, and Markets

    $2,625.00 – $5,250.00
  • Placeholder image

    Advanced Drug Delivery: Technologies, Applications, and Markets

    $2,625.00 – $5,250.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain  June 24, 2025
  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Drug Delivery Markets: Oral DeliveryIn Vitro Diagnostic Tests and Systems: The World Outside the United States
Scroll to top